# OnCo record nct06951997 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06951997/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06951997", "NCT06951997" ;
  schema:name "QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer"@en ;
  schema:description "A phase 2 trial of iparomlimab and tuvonralimab, tucidinostat (chidamide), gemcitabine and nab-paclitaxel in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06951997/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06951997> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/iparomlimab-tuvonralimab/>, <https://onco.cc/drugs/tucidinostat/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/nab-paclitaxel/> .